STOCK TITAN

Dianthus Therapeutics CFO sells 124,042 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Dianthus Therapeutics, Inc. EVP, CFO & CBO Ryan Savitz exercised options for 124,042 common shares from November 9 through November 12, 2026, and sold 124,042 common shares over the same dates. Option exercise prices were $8.44, $17.88, $21.77 and $22.07 per share. The transactions were made under a Rule 10b5-1 trading plan adopted August 7, 2026.

Insider Savitz Ryan
Role EVP, CFO & CBO
Sold 124,042 shs ($11.23M)
Approx. gross sale proceeds $11.23M
Approx. exercise cost $2.47M
Approx. pre-tax spread $8.76M
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F1, F12 1,339 $0.00 $0.00
Exercise Stock Option (Right to Buy) F1, F13 16,385 $0.00 $0.00
Exercise Common Stock F1 1,339 $21.77 $29K
Exercise Common Stock F1 16,385 $22.07 $362K
Sale Common Stock F1, F10 17,724 $90.56 $1.61M
Exercise Stock Option (Right to Buy) F1, F12 1,744 $0.00 $0.00
Exercise Stock Option (Right to Buy) F1, F13 1,300 $0.00 $0.00
Exercise Common Stock F1 1,744 $21.77 $38K
Exercise Common Stock F1 1,300 $22.07 $29K
Sale Common Stock F1, F9 3,044 $90.03 $274K
Exercise Stock Option (Right to Buy) F1, F12 1,301 $0.00 $0.00
Exercise Stock Option (Right to Buy) F1, F13 1,260 $0.00 $0.00
Exercise Common Stock F1 1,301 $21.77 $28K
Exercise Common Stock F1 1,260 $22.07 $28K
Sale Common Stock F1, F8 2,561 $90.14 $231K
Exercise Stock Option (Right to Buy) F1, F11 29,276 $0.00 $0.00
Exercise Stock Option (Right to Buy) F1, F12 20,608 $0.00 $0.00
Exercise Stock Option (Right to Buy) F1, F13 40,430 $0.00 $0.00
Exercise Stock Option (Right to Buy) F1, F14 10,399 $0.00 $0.00
Exercise Common Stock F1 29,276 $17.88 $523K
Exercise Common Stock F1 20,608 $21.77 $449K
Exercise Common Stock F1 40,430 $22.07 $892K
Exercise Common Stock F1 10,399 $8.44 $88K
Sale Common Stock F1, F2 300 $85.16 $26K
Sale Common Stock F1, F3 700 $86.70 $61K
Sale Common Stock F1, F4 1,736 $88.84 $154K
Sale Common Stock F1, F5 37,517 $90.12 $3.38M
Sale Common Stock F1, F6 58,396 $90.90 $5.31M
Sale Common Stock F1, F7 2,064 $91.59 $189K
Holdings After Transaction: Stock Option (Right to Buy) — 176,884 options (Direct); Common Stock — 0 shares (Direct)
Footnotes (14)
  1. F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2026.
  2. F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.09 to $85.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.36 to $87.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.21 to $89.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. F5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.44 to $90.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  6. F6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.44 to $91.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  7. F7. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.46 to $92.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  8. F8. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.00 to $90.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  9. F9. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.00 to $90.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  10. F10. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.00 to $90.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  11. F11. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
  12. F12. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
  13. F13. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
  14. F14. The shares of common stock underlying this stock option award vested as to 25% of the shares on June 2, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Options exercised 124,042 shares November 9–12, 2026
Shares sold 124,042 shares November 9–12, 2026
Option exercise price $8.44 per share For 10,399 shares exercised November 9, 2026
Option exercise price $17.88 per share For 29,276 shares exercised November 9, 2026
Option exercise price $21.77 per share Reported for option exercises from November 9–12, 2026
Option exercise price $22.07 per share Reported for option exercises from November 9–12, 2026
Weighted-average sale price $85.16 per share 300 shares sold November 9, 2026
Weighted-average sale price $90.56 per share 17,724 shares sold November 12, 2026
Rule 10b5-1 trading plan regulatory
"pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many DNTH shares did Ryan Savitz sell, and at what prices?

Ryan Savitz sold 124,042 common shares from November 9 through November 12, 2026. Reported weighted-average prices included $85.16 for 300 shares on November 9 and $90.56 for 17,724 shares on November 12. The sales were made under a Rule 10b5-1 plan adopted August 7, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Savitz Ryan

(Last)(First)(Middle)
C/O DIANTHUS THERAPEUTICS, INC.
7 TIMES SQUARE, 43RD FLOOR

(Street)
NEW YORK NEW YORK 10036

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Dianthus Therapeutics, Inc. /DE/ [ DNTH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, CFO & CBO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/09/2026M(1)29,276A$17.8829,276D
Common Stock11/09/2026M(1)20,608A$21.7749,884D
Common Stock11/09/2026M(1)40,430A$22.0790,314D
Common Stock11/09/2026M(1)10,399A$8.44100,713D
Common Stock11/09/2026S(1)300D$85.16(2)100,413D
Common Stock11/09/2026S(1)700D$86.7(3)99,713D
Common Stock11/09/2026S(1)1,736D$88.84(4)97,977D
Common Stock11/09/2026S(1)37,517D$90.12(5)60,460D
Common Stock11/09/2026S(1)58,396D$90.9(6)2,064D
Common Stock11/09/2026S(1)2,064D$91.59(7)0D
Common Stock11/10/2026M(1)1,301A$21.771,301D
Common Stock11/10/2026M(1)1,260A$22.072,561D
Common Stock11/10/2026S(1)2,561D$90.14(8)0D
Common Stock11/11/2026M(1)1,744A$21.771,744D
Common Stock11/11/2026M(1)1,300A$22.073,044D
Common Stock11/11/2026S(1)3,044D$90.03(9)0D
Common Stock11/12/2026M(1)1,339A$21.771,339D
Common Stock11/12/2026M(1)16,385A$22.0717,724D
Common Stock11/12/2026S(1)17,724D$90.56(10)0D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$17.8811/09/2026M(1)29,276 (11)01/23/2034Common Stock29,276$042,500D
Stock Option (Right to Buy)$21.7711/09/2026M(1)20,608 (12)05/22/2034Common Stock20,608$048,143D
Stock Option (Right to Buy)$22.0711/09/2026M(1)40,430 (13)02/03/2035Common Stock40,430$0109,570D
Stock Option (Right to Buy)$8.4411/09/2026M(1)10,399 (14)06/06/2032Common Stock10,399$00D
Stock Option (Right to Buy)$21.7711/10/2026M(1)1,301 (12)05/22/2034Common Stock1,301$046,842D
Stock Option (Right to Buy)$22.0711/10/2026M(1)1,260 (13)02/03/2035Common Stock1,260$0108,310D
Stock Option (Right to Buy)$21.7711/11/2026M(1)1,744 (12)05/22/2034Common Stock1,744$045,098D
Stock Option (Right to Buy)$22.0711/11/2026M(1)1,300 (13)02/03/2035Common Stock1,300$0107,010D
Stock Option (Right to Buy)$21.7711/12/2026M(1)1,339 (12)05/22/2034Common Stock1,339$043,759D
Stock Option (Right to Buy)$22.0711/12/2026M(1)16,385 (13)02/03/2035Common Stock16,385$090,625D
Explanation of Responses:
1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2026.
2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.09 to $85.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.36 to $87.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.21 to $89.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.44 to $90.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.44 to $91.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
7. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.46 to $92.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
8. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.00 to $90.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
9. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.00 to $90.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
10. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.00 to $90.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
11. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
12. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
13. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
14. The shares of common stock underlying this stock option award vested as to 25% of the shares on June 2, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
/s/ Adam Veness, as attorney-in-fact for Ryan Savitz11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading